Introduction

▼
Postpartum depression is a common and serious mental health problem that is associated with maternal suffering and numerous negative consequences for offspring [1] . It has been reported that 10-15 % of women suffer postpartum depression following childbirth [2] . Postpartum depression can harm the mother and child relationship, which in turn negatively impacts children in terms of nutrition and care, as well as physical and mental development [3] . Selfesteem, childcare stress, life stress, social support, marital relationship, infant temperament, marital status, socioeconomic status, unwanted pregnancy, previous psychiatric disorder, method of childbirth, previous abortion and biological changes are related to postpartum depression [2] . Etiologies of mood balance, depressive disor-Introduction: Postpartum depression is a common mental health problem that is associated with maternal suffering. The aim of this doubleblind clinical trial was to compare safety and efficacy of saffron and fluoxetine in treatment of mild to moderate postpartum depression. Methods: This was a 6-week, double-blind, randomized clinical trial. Subjects were women aged 18-45 years with mild to moderate postpartum depression who had Hamilton Depression Rating Scale (HDRS 17-item) score ≤ 18. Eligible participants were randomized to receive either a capsule of saffron (15 mg capsule) or fluoxetine (20 mg capsule) twice daily for 6 weeks. The primary outcome measure was to evaluate efficacy of saffron compared to fluoxetine in improving depressive symptoms (HDRS score).
Results:
There was no significant effect for time × treatment interaction on HDRS score [F (4.90, 292.50) = 1.04, p = 0.37] between the 2 groups. 13 (40.60 %) patients in the saffron group experienced complete response ( ≥ 50 % reduction in HDRS score) compared with 16 (50 %) in the fluoxetine group and the difference between the 2 groups was not significant in this regard (p = 0.61). Frequency of adverse events was not significantly different between the treatment groups. Discussion: The results of this study may suggest that saffron is a safe alternative medication for improving depressive symptoms of postpartum depression. Nevertheless, it should be mentioned that the trial is not well powered and should be considered a preliminary study. Therefore, large clinical trials with longer treatment periods and comparison with placebo group would be appropriate for future studies.
tional medicine, it is used to treat menstrual disorder, difficult labor, inflammation, vomiting and diseases affecting the throat [18] [19] [20] . Several controlled studies have shown beneficial effects of Crocus sativus on depression, premenstrual symptoms and Alzheimer's disease [19, [21] [22] [23] [24] [25] [26] . Our objective was to compare the efficacy of Crocus sativus (stigma) with fluoxetine in treatment of mild to moderate postpartum depression in a 6-week, double-blind, randomized clinical trial.
Method
▼
Trial design
A 6-week, multicenter, randomized, double-blind, parallel- 
Participants
Women between 18-45 years of age, with a diagnosis of postpartum depression based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria were eligible to participate in the trial (4-12 weeks after childbirth). Patients were required to have mild to moderate postpartum depression at time of randomization, having a score ≥ 10 and ≤ 18 in the 17-item Hamilton Depression Rating Scale (HDRS) [27, 28] . Exclusion criteria included: women with psychotic depression, history of suicidal or infanticidal thoughts, a history of bipolar disorder, substance or alcohol dependence (with the exception of nicotine dependence), lactation, hypothyroidism and acute medical illness. Patients suffering from any diagnosis other than postpartum depression on the DSM-IV-TR axis I were also excluded.
Interventions
Patients underwent a standard clinical assessment comprising a psychiatric evaluation, a structured diagnostic interview and medical history. Eligible participants were randomized to receive either a capsule of saffron (SaffroMood ® , IMPIRAN, containing 15 mg of saffron extract) twice daily or a fluoxetine capsule (Abidi, Iran, 20 mg capsule; each capsule had 1.65-1.75 mg crocin) twice daily for 6 weeks. Participants were not allowed to use any psychotropic drug or receive any behavioral intervention therapy during the course of the trial.
Outcome
All participants were assessed using HDRS score at baseline and at weeks 1, 3 and 6. The HDRS contains 17 questions (on a 3-point or 5-point scale) that assess severity of depressive symptoms. This scale has been applied in many clinical trials in Iran exploring depression therapeutic efficacy [27] [28] [29] [30] [31] [32] . The primary outcome measure of this trial was to evaluate efficacy of saffron compared to fluoxetine in improving depressive symptoms in postpartum individuals using general linear model repeated measures. The 2 groups were also compared regarding improvement in HDRS scores from baseline HDRS score at each time point, partial responders (25-50 % reduction in the HDRS score), responders ( ≥ 50 % reduction in HDRS score), remitters (HDRS score ≤ 7) and the time needed to respond to treatment. Response rate ( ≥ 50 % decrease in the HDRS score) and remission rate (HDRS score ≤ 7) were compared between 2 groups. In terms of adverse events, a 25-item checklist was provided to systematically record the adverse events during the course of the trial. All participants were asked about any adverse event that was not mentioned in the checklist. Participants were also asked to immediately inform the research team about any unexpected symptom during the study period.
Sample size estimation
Assuming a mean difference of 3 on the HDRS score between the saffron and the fluoxetine groups, with a standard deviation (SD) of 3 on HDRS score, a power of 95 % and a 2-tailed significance level of 0.05, 27 patients were needed in each group. Moreover, after assuming 25 % attrition rate, 34 patients were needed in each group.
Randomization, allocation concealment and blinding
An independent party, who was not involved elsewhere in the trial, randomized codes by permuted randomization block (blocks of 4, allocation ratio 1:1). Concealment of allocation was performed using sequentially numbered, sealed opaque envelopes. An aluminum foil inside the envelopes kept them impermeable to intense light. Study participant, research investigator and the rater were all blind to the treatment allocation. Saffron and fluoxetine capsules were indistinguishable in their shape, size, texture, color and odor.
Statistical analyses
Frequency of categorical variables and mean ± SD of continuous variables are reported. General linear model repeated measure was used to compare HDRS scores between the saffron and the fluoxetine groups. Whenever Mauchly's test of sphericity was significant, Greenhouse-Geisser adjustment was used for degrees of freedom. Independent t-test was used to compare mean of continuous variables between treatment groups. Categorical variables were compared using chi-square test and Fisher's exact test where appropriate. Statistical analysis was performed using Statistical Package of Social Science Software (SPSS version 20, IBM Company, USA).
Results
▼
Among 94 women who were screened for the eligibility criteria, 68 women were entered into the trial and randomized to receive either saffron (n = 34) or fluoxetine (n = 34). 4 women were excluded from the trial due to their shift to moderate to severe depression, and a total number of 64 patients (32 patients in each group) completed the trial ( • ▶ Fig. 1 ). Baseline characteristics of the study participants were not significantly different between the treatment groups ( • ▶ Table 1 ). Fig. 2) . There was no significant difference between the 2 groups in terms of reduction in HDRS score from baseline to each time, for partial responders, responders and remitters Table 2 ). Remission rates were almost equal between 2 groups as • ▶ Table 2 shows 6 (18.8 %) patients in the saffron group and 7 (21.9 %) in the fluoxetine group reached a HDRS ≤ 7 by the end of this trial (p = 1.00). 13 (40.60 %) patients in the saffron group experienced complete response ( ≥ 50 % reduction in HDRS score) compared with 16 (50 %) in the fluoxetine group, and the difference between the 2 groups was not significant in this regard (p = 0.61). Partial response rates were not significantly different between the 2 groups as well; all 32 patients in the both group who completed the trial show ≥ 25 % reduction in HDRS score by week 6 (p = 1.00).
Side effects
The frequencies of adverse events observed during the trial are summarized in • ▶ Table 3 . Patients in the fluoxetine group experienced more headache, dry mouth, daytime drowsiness, constipation and sweating than the saffron group. However, frequencies of adverse events were not significantly different between the 2 groups. No major adverse event and no death occurred.
Discussion ▼
A postpartum depression takes a great toll on women and negatively affects social interaction and infant development [3] . Mood control, especially the etiology of depressive disorders, is not completely understood. However, substantial evidence has accumulated that serotonergic systems play a central role [4] [5] [6] [7] . Saffron is used as an antispasmodic, eupeptic, gingival, sedative, anticatarrhal, nerve sedative, carminative, diaphoretic, expectorant, stimulant, stomachic, aphrodisiac and antidepressant [18] . The search for new and more effective therapeutic agents includes the study of plants used in traditional medicine to treat mental disorders [13] . Saffron is used for the treatment of depression in Persian traditional medicine [22] . Corcin and safranal, 2 major components of saffron, inhibit reuptake of dopamine, norepinephrine and serotonin [19] . This study was carried out to compare the antidepressant effect of saffron with fluoxetine in mild to moderate postpartum depression. The results of this study emphasize saffron is a safe alternative and as effective as fluoxetine in improving symptoms of depression.
In this double-blind, randomized clinical trial, Crocus sativus was found to be effective almost like fluoxetine. Our findings are in line with recently published studies that show Crocus sativus antidepressant effect [19, [21] [22] [23] [24] 33] . A trial that compared the petal of Crocus sativus and fluoxetine in the treatment of depressed patients showed that the petal of Crocus sativus is as effective as fluoxetine [21] . Another clinical trial demonstrated that saffron is as effective as imipramine in treatment of mild to moderate depression. Also, in the imipramine group, anticholin- Fig. 1 Flow diagram of the study. ergic effects such as dry mouth and sedation were observed more often as predicted [22] . A placebo-controlled trial showed that patients with mild to moderate depression receiving saffron experienced statistically significant benefits in their mood after 6 weeks of treatment compared to placebo [23] . In another clinical trial, saffron was found to be effective in relieving symptoms of PMS [24] . Shahmansouri et al. showed that short-term therapy with saffron capsules was associated with the same antidepressant efficacy in comparison with fluoxetine in patients with a prior history of post percutaneous coronary intervention who were suffering from depression [33] . In our study, patients in the fluoxetine group experienced more headache, dry mouth, daytime drowsiness, constipation and sweating than the saffron group. However, frequencies of adverse events were not significantly different between the 2 groups. Limitations of the present trial include lack of a placebo group, a small number of participants and short period of follow-up. Since the trial is not well powered, large clinical trials with longer treatment periods and comparison with placebo group would be appropriate for future studies. It should be mentioned that the trial was the first study of saffron in the treatment of postpartum depression. Therefore, we recruited only mild to moderate depression and, as a result of this, the SD of severity score in the participants was quite small. In addition, the findings of this study cannot be generalized to severe depression. Nevertheless, the results of this study emphasize efficacy of saffron in treatment of postpartum depression. On the other hand, the fewer side effects of saffron compared with the classical antidepressant confirm application of saffron as an alternative treatment of depression in traditional medicine.
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